ABIONYX Pharma S.A.
Common Stock · EUR · EPA
Price
€2.9
Cap
€80.26M
Earnings
—
30d Trend
-20.2%
56% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 40×Macro 0.99 (−1%)=40
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
5-10 day swing — oversold bounce candidate
BRAIN47'S ASSESSMENT
I rate ABIONYX Pharma S.A. at 40/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 60/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-16.7%
3 MONTHS
-14.3%
12 MONTHS
+127.4%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
5-10 day swing — oversold bounce candidate. Momentum (60) and Quality (37) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 56%. I classify this as a speculative position — elevated volatility at 56% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.